Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity.

Zilli T, Rouzaud M, Jorcano S, Dipasquale G, Nouet P, Toscas JI, Casanova N, Wang H, Escude L, Molla M, Linero D, Weber DC, Miralbell R.

Technol Cancer Res Treat. 2010 Jun;9(3):263-70.

PMID:
20441236
2.

Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.

Zilli T, Jorcano S, Rouzaud M, Dipasquale G, Nouet P, Toscas JI, Casanova N, Wang H, Escudé L, Mollà M, Linero D, Weber DC, Miralbell R.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):382-9. doi: 10.1016/j.ijrobp.2010.05.057.

PMID:
20884129
3.

Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.

Teh BS, Mai WY, Uhl BM, Augspurger ME, Grant WH 3rd, Lu HH, Woo SY, Carpenter LS, Chiu JK, Butler EB.

Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):705-12.

PMID:
11172952
4.

Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?

Kountouri M, Zilli T, Rouzaud M, Dubouloz A, Linero D, Escudé L, Jorcano S, Miralbell R.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):272-9. doi: 10.1016/j.ijrobp.2015.10.055.

PMID:
26853336
5.

Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.

Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e415-21. doi: 10.1016/j.ijrobp.2011.01.024.

PMID:
21477939
6.

Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.

Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058.

PMID:
21163587
7.

Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8. doi: 10.1016/j.ijrobp.2013.07.041.

8.

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):57-64. doi: 10.1016/j.ijrobp.2009.01.048.

PMID:
19395192
9.

Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.

Miralbell R, Mollà M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, Sanz S, Ares C, Jorcano S, Linero D, Escudé L.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):50-7. doi: 10.1016/j.ijrobp.2009.07.1689.

PMID:
19910135
10.

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043.

PMID:
20171807
11.

Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.

Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1074-84. doi: 10.1016/j.ijrobp.2014.01.015.

PMID:
24661661
12.

Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.

Lopez Guerra JL, Isa N, Matute R, Russo M, Puebla F, Kim MM, Sanchez-Reyes A, Beltran C, Jaen J, Bourgier C, Marsiglia H.

Clin Transl Oncol. 2013 Apr;15(4):271-7. doi: 10.1007/s12094-012-0907-y.

PMID:
22855189
13.

High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.

De S, Kannan V, Deshpande S, Anand V, Ghadi Y.

J Cancer Res Ther. 2010 Jan-Mar;6(1):58-64. doi: 10.4103/0973-1482.63565.

14.

Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.

Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, Both S.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1389-96. doi: 10.1016/j.ijrobp.2011.04.041.

PMID:
21664069
15.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018.

16.

A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.

Lock M, Best L, Wong E, Bauman G, D'Souza D, Venkatesan V, Sexton T, Ahmad B, Izawa J, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1306-15. doi: 10.1016/j.ijrobp.2010.04.054.

PMID:
20708855
17.
18.

Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.

Deville C, Both S, Bui V, Hwang WT, Tan KS, Schaer M, Tochner Z, Vapiwala N.

Radiat Oncol. 2012 May 23;7:76. doi: 10.1186/1748-717X-7-76.

19.

Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.

Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.

Cancer. 2009 Dec 1;115(23):5596-606. doi: 10.1002/cncr.24558.

20.

Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.

Guckenberger M, Ok S, Polat B, Sweeney RA, Flentje M.

Strahlenther Onkol. 2010 Oct;186(10):535-43. doi: 10.1007/s00066-010-2144-z. Erratum in: Strahlenther Onkol. 2010 Dec;186(12):705.

PMID:
20890743

Supplemental Content

Support Center